The Current Role of Angiogenesis Inhibitors in the Treatment of Renal Cell Carcinoma

Seminars in Oncology

Volumn 33, Issue 5, 2006, Pages 596-606

  Choueiri, Toni K ^a   Bukowski, Ronald M ^a   Rini, Brian I ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; HYBRID PROTEIN; IMATINIB; INTERLEUKIN 2; PAZOPANIB; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB;

ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CYTOPENIA; DESQUAMATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; META ANALYSIS; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; FORECASTING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749448871     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.06.003     Document Type: Article

References (83)

1. Coppin C., Porzsolt F., Awa A., et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) CD001425
2. Clifford S.C., and Maher E.R. Von Hippel-Lindau disease: Clinical and molecular perspectives. Adv Cancer Res 82 (2001) 85-105
3. Gnarra J.R., Lerman M.I., Zbar B., et al. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 22 (1995) 3-8
4. Kondo K., Yao M., Yoshida M., et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 34 (2002) 58-68
5. Gallou C., Joly D., Mejean A., et al. Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 13 (1999) 464-475
6. Schraml P., Struckmann K., Hatz F., et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 196 (2002) 186-193
7. Clifford S.C., Prowse A.H., Affara N.A., et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22 (1998) 200-209
8. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91 (1994) 9700-9704
9. Kibel A., Iliopoulos O., DeCaprio J.A., et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269 (1995) 1444-1446
10. Krieg M., Haas R., Brauch H., et al. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19 (2000) 5435-5443
11. Gnarra J.R., Zhou S., Merrill M.J., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 93 (1996) 10589-10594
12. Goodsell D.S. The molecular perspective: VEGF and angiogenesis. Oncologist 7 (2002) 569-570
13. Kourembanas S., Hannan R.L., and Faller D.V. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 86 (1990) 670-674
14. de Paulsen N., Brychzy A., Fournier M.C., et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 98 (2001) 1387-1392
15. Kuwabara K., Ogawa S., Matsumoto M., et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci U S A 92 (1995) 4606-4610
16. Grabmaier K., de Weijert M.C., Verhaegh G.W., et al. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 23 (2004) 5624-5631
17. Lee Y.S., Vortmeyer A.O., Lubensky I.A., et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 11 (2005) 1059-1064
18. Giordano F.J., and Johnson R.S. Angiogenesis: The role of the microenvironment in flipping the switch. Curr Opin Genet Dev 11 (2001) 35-40
19. Goodsell D.S. The molecular perspective: VEGF and angiogenesis. Stem Cells 21 (2003) 118-119
20. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 (1997) 4593-4599
21. Dagnaes-Hansen F., Rasmussen L.M., Tilton R., et al. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma. Anticancer Res 23 (2003) 1625-1630
22. Margolin K., Gordon M.S., Holmgren E., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 19 (2001) 851-856
23. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19 (2001) 843-850
24. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
25. Motzer R.J., Mazumdar M., Bacik J., et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
26. Yang J.C. Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res 10 (2004) 6367S-63S
27. Elaraj D.M., White D.E., Steinberg S.M., et al. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother 27 (2004) 259-264
28. Rini B.I., Halabi S., Taylor J., et al., Cancer and Leukemia Group B 90206. A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10 (2004) 2584-2586
29. Gabrilovich D.I., Ishida T., Nadaf S., et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5 (1999) 2963-2970
30. Laxmanan S., Robertson S.W., Wang E., et al. Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. Biochem Biophys Res Commun 334 (2005) 193-198
31. Knebelmann B., Ananth S., Cohen H.T., et al. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 58 (1998) 226-231
32. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61 (2001) 5090-5101
33. Hainsworth J.D., Sosman J.A., Spigel D.R., et al. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 (2005) 7889-7896
34. Data on file. South San Francisco, CA, Genentech Inc. Press release, October 18, 2005. http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8967; accessed November 11, 2005
35. Hainsworth J.D., Sosman J.A., Spigel D.R., et al. Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial. Proc Am Soc Clin Oncol 23 (2005) 16S (abstr 4242)
36. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99 (2002) 11393-11398
37. Konner J., and Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 4 suppl 2 (2004) S81-S85
38. Dupont J., Shwartz L.L., Koutcher J., et al. Phase I and pharmacakinetic study of VEGF Trap administered subcutaneously (sc) to patients with advanced solid malignancies. Proc Am Soc Clin Oncol 23 (2004) 16S (abstr 3009)
39. Dupont J., Rothenberg M., Spriggs D.R., et al. Safety and pharmacokinetic of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. Proc Am Soc Clin Oncol 23 (2005) 16S (abstr 3029)
40. Bergers G., Song S., Meyer-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
41. Sulzbacher I., Birner P., Traxler M., et al. Expression of platelet-derived growth factor-alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol 120 (2003) 107-112
42. Heldin C.H., and Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79 (1999) 1283-1316
43. Bhardwaj B., Klassen J., Cossette N., et al. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 2 (1996) 773-782
44. Sundberg C., Branting M., Gerdin B., et al. Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of platelet-derived growth factor-AB/BB to stromal cells. Am J Pathol 151 (1997) 479-492
45. Xu L., Tong R., Cochran D.M., et al. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65 (2005) 5711-5719
46. Sun L., Tran N., Tang F., et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 41 (1998) 2588-2603
47. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
48. Abrams T.J., Lee L.B., Murray L.J., et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2 (2003) 471-478
49. Murray L.J., Abrams T.J., Long K.R., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20 (2003) 757-766
50. Yee K.W., Schittenhelm M., O'Farrell A.M., et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 104 (2004) 4202-4209
51. Marzola P., Degrassi A., Calderan L., et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 11 (2005) 5827-5832
52. Demetri G.D., Desai J., Fletcher J.A., et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22 (2005) 14S (abstr 3001)
53. Fiedler W., Serve H., Dohner H., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105 (2005) 986-993
54. Manning W.C., Bello C.L., Deprimo S.E., et al. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant GIST. Proc Am Soc Clin Oncol 22 (2003) 14S (abstr 768)
55. Rosen L., Mulay M., Long J., et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22 (2003) 14S (abstr 765)
56. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
57. Motzer R., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 1-8
58. Motzer R.J., Rini B., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2005) 2516-2524
59. DePrimo S.E., Bello C.L., Smeraglia J., et al. Soluble protein biomarkers of pharmacodynamic activity of the multi-targeted kinase inhibitor SU11248 in patients with metastatic renal cell cancer. Proc Am Assoc Cancer Res 46 (2005) (abstr 464)
60. Beeram M., Patnaik A., and Rowinsky E.K. Raf: A strategic target for therapeutic development against cancer. J Clin Oncol 23 (2005) 6771-6790
61. Lee Jr. J.T., and McCubrey J.A. Targeting the Raf kinase cascade in cancer therapy-novel molecular targets and therapeutic strategies. Exp Opin Ther Targets 6 (2002) 659-678
62. Bos J.L. The ras gene family and human carcinogenesis. Mutat Res 195 (1988) 255-271
63. Dasgupta P., Sun J., Wang S., et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 24 (2004) 9527-9541
64. Oka H., Chatani Y., Hoshino R., et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55 (1995) 4182-4187
65. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
66. Wilhelm S., and Chien D.S. BAY 43-9006: Preclinical data. Curr Pharm Des 8 (2002) 2255-2257
67. Lyons J.F., Wilhelm S., Hibner B., et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8 (2001) 219-225
68. Awada A., Hendlisz A., Gil T., et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92 (2005) 1855-1861
69. Clark J.W., Eder J.P., Ryan D., et al. Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11 (2005) 5472-5480
70. Moore M., Hirte H.W., Siu L., et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16 (2005) 1688-1694
71. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
72. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib. J Clin Oncol 24 (2006) 2505-2512
73. Escudier B.S.C., Szczylik C., Eisen T., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23 (2005) 16S (abstr 4510)
74. Inai T., Mancuso M., Hashizume H., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165 (2004) 35-52
75. Rugo H.S., Herbst R.S., Liu G., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23 (2005) 5474-5483
76. Liu G., Rugo H.S., Wilding G., et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J Clin Oncol 23 (2005) 5464-5473
77. Rini B., Rixe O., Bukowski R.M., et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 23 (2005) 16S (abstr 4509)
78. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 (2000) 2178-2189
79. Drevs J., Hofmann I., Hugenschmidt H., et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60 (2000) 4819-4824
80. George D., Michaelson D., Oh W.K., et al. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 22 (2003) 385 (abstr 1548)
81. Hecht J.R., Trarbach T., Jaeger E., et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol 23 (2005) 16S (abstr 3)
82. Kumar R., Harrington L.E., Hopper T.M., et al. Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. Proc Am Soc Clin Oncol 23 (2005) 16S (abstr 9537)
83. Hurwitz H., Dowlati A., Savage S., et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. Proc Am Soc Clin Oncol 23 (2005) 16S (abstr 3012)